Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin Add-on to Empagliflozin and Metformin in T2DM
NCT01778049Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Jan 2013; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01778049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01778049.